NOVA LEAH continues to set the standard for cybersecurity risk management solutions in the medical device industry

The experts at Nova Leah have developed SelectEvidence® to address the industry drivers and challenges facing medical device manufactures today and in the future.

SelectEvidence® is a turnkey collaborative cybersecurity expert system that supports medical device manufacturers in designing, verifying and certifying connected medical devices to meet these FDA guidelines and industry security standards. It also assists healthcare providers in the selection, acquisition and risk management of medical devices on their healthcare networks.

SelectEvidence® allows stakeholders to identify cybersecurity requirements for their devices using proven standards within a collaborative framework. SelectEvidence® is supported by state of the art repositories and machine learning capabilities which inform each step of the risk management process providing full traceability from risk identification to treatment.

SelectEvidence® facilitates and informs all premarket and postmarket risk management activities. With the functionality to import a Software Bill of Materials (sBoM), SelectEvidence® continuously surveys for newly identified vulnerabilities alerting users to these findings and suggested mitigations. The system is a cradle to grave solution, managing cybersecurity processes from product development, market approval, integration, use, to product retirement.

SelectEvidence® can be deployed as a standalone cybersecurity expert system for an individual stakeholder or can be used as a collaborative solution for managing risk and information sharing between both manufacturers and healthcare providers.

For more information about Nova Leah, visit our homepage.